Efficacy of Antituberculous Therapy in Management of Sarcoidosis
Summary
From the time sarcoidosis has been described, there has always been a belief that the disease is in some way related to tuberculosis. If indeed tuberculosis is a causal factor in sarcoidosis, then the hypothesis can be further reinforced, if anti-tubercular therapy (ATT) is useful in treatment of sarcoidosis. Very few trials have been conducted in the past but the results of these trials have been discouraging. These trials were generally small studies and limited by time bias and used older regimens based on isoniazid, amino-salicylic acid and streptomycin. In our experience nearly one third of patients who are finally diagnosed to have sarcoidosis, have received ATT for variable length of time, but its impact of final outcome of sarcoidosis has not been studied. The aim of this prospective randomized controlled trial (RCT) is to evaluate the efficacy and safety of Rifampicin and Isoniazid along with prednisolone compared to prednisolone alone in treatment of Sarcoidosis.
Timeline
- Start
- 2009-01
- Primary completion
- 2012-12
- Completion
- 2013-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | INH | Unknown | 300 mg | — |
| Comparator | Rifampin | Small molecule | 450 mg | — |
| Comparator | Rifampin | Small molecule | 600 mg | — |
| Comparator | Prednisolone | Other / unclassified | 0.25 mg/kg | — |